Slide 1: Third Quarter Fiscal Year 2025 Earnings Presentation
AngioDynamics Third Quarter Fiscal Year 2025 Earnings Presentation April 2, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: FY Q3 2025 Key Takeaways
FY Q3 2025 Key Takeaways Continued commercial and operational execution positions AngioDynamics to drive accelerated, profitable growth moving forward CONTINUED COMMERCIAL EXECUTION • 9% YoY pro forma total revenue growth • MedTech segment pro forma revenue growth of 22% YoY • Auryon sales of $13.9
Slide 4: Q3 FY 2025 Pro Forma Financial Snapshot
Q3 FY 2025 Pro Forma Financial Snapshot Net Sales Segment Revenue Contribution $72.0 Q3 24 Q3 25 $66.0 39% $31.3 22.2% 44% $25.7 Pro Forma Growth 61% 56% Med Device Med Tech Med Device Med Tech 0.9% $40.3 $40.7 Pro Forma Growth Segment Gross Margin Q3 24 Q3 25 47.4% 62.5% Med Device Med Tech Med Dev
Slide 5: YTD FY 2025 Pro Forma Financial Snapshot
YTD FY 2025 Pro Forma Financial Snapshot Net Sales Segment Revenue Contribution $212.5 $199.6 YTD 24 YTD 25 $76.6 $90.9 38% 18.6% 43% Pro Forma Growth 57% 62% Med Device Med Tech Med Device Med Tech $123.0 $121.7 (1.1)% Pro Forma Growth Segment Gross Margin YTD 24 YTD 25 47.8% 63.2% Med Device Med T
Slide 6: Med Tech - Auryon
Med Tech - Auryon Period Sales YoY Growth Q3 2025 $13.9M 17.3% YTD 2025 $41.3M 21.2% • Cumulative sales of ~$170M since launch in Sept 2020 • Continued penetration into hospital setting • Launched 1.7mm Catheter in Q1 FY25 • European CE Mark approval in Q1 FY25 • Initiated the AMBITION BTK RCT and R
Slide 7: Med Tech - Thrombus Management
Med Tech - Thrombus Management 3Q 2025 Sales YoY Growth YTD 2025 Sales YoY Growth AngioVac $6.8M 23.1% AngioVac $20.7M 20.2% AlphaVac $3.0M 161.4% AlphaVac $7.7M 59.0% Total Mech Thromb. $9.8M 46.7% Total Mech Thromb. $28.4M 28.7% Unifuse $1.4M 17.3% Unifuse $3.8M 13.4% Total Thrombus Mgmt. $11.2M 4
Slide 8: Med Tech - NanoKnife
Med Tech - NanoKnife 3Q 2025 Sales YoY Growth YTD 2025 Sales YoY Growth Disposables $4.9M 16.2% Disposables $14.0M 11.3% Capital $1.3M (21.6)% Capital $3.3M (26.5)% Total $6.3M 5.3% Total $17.3M 1.3% • Received CPT Category 1 Code (effective Jan. 1, 2026), which is expected to streamline reimburseme
Slide 9: Med Device
Med Device 3Q 2025 Sales YoY Growth YTD 2025 Sales YoY Growth Core Peripheral $19.4M 3.5% Core Peripheral $56.8M 0.5% Venous / EVLT $6.6M (2.8)% Venous / EVLT $20.1M (0.2)% Ports $8.7M (2.1)% Ports $26.9M 0.3% Solero Microwave $4.6 8.6% Solero Microwave $13.5M (7.2)% Alatus and Isoloc Balloons $0.9M
Slide 10: Fiscal Year 2025 Guidance
Fiscal Year 2025 Guidance Metric Updated Guidance Previous Guidance (Issued Apr. 2, 2025) (Issued Jan. 8, 2025) Full Year Net Sales $285 - $288 million $282 - $288 million Med Tech Net Sales 14 – 16% YoY growth 12 – 15% YoY growth Med Device Net Sales Flat (unchanged) Flat Gross Margin 53 - 54% 52 -
Slide 11: Fiscal Year 2025 Catalysts
Fiscal Year 2025 Catalysts Auryon • Received CE Mark in Q1 FY2025 • Moved to full market release in EU during first quarter of calendar 2025 • Continuing to increase penetration in the hospital setting in the U.S. AlphaVac • Executing full commercial launch of PE indication in U.S. and CE Marked cou
Slide 12: Appendix
Appendix 12
Slide 13: Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements
Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements 13
Slide 14: Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Income (Loss) and EPS
Reconciliation of GAAP Net Loss to Non- Reconciliation of Net Loss to Adjusted GAAP Adjusted Net Income (Loss) and EPS EBITDA 14
Slide 15: Reconciliation of Non-GAAP Pro Forma Net Loss to Adjusted Pro Forma Net Loss
Reconciliation of Non-GAAP Pro Forma Reconciliation of Non-GAAP Pro Forma Net Loss to Adjusted Pro Forma Net Loss Net Loss to Adjusted Pro Forma EBITDA and EPS 15
Slide 16: Detail of Acquisition, Restructuring and Other Items, net
Detail of “Acquisition, Restructuring and Other Items, net” 16
Slide 17: Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category
Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category 17